KDM8: A Potential Drug Target and Biomarker for Epilepsy (G79831)

Target Name: KDM8

NCBI ID: G79831

KDM8

KDM8: A Potential Drug Target and Biomarker for Epilepsy

Epilepsy is a chronic neurological disorder that affects millions of people worldwide, characterized by recurrent episodes of severe convulsions, automata, and diverse neurological deficits. Despite being a common condition, the etiology and pathophysiology of epilepsy remain largely unresolved, and current treatment options are often limited in their effectiveness. The search for new and innovative therapies has led to the exploration of gene expression and epigenetic mechanisms in the pathogenesis of epilepsy. One promising candidate for drug targeting and biomarker development is KDM8, a lysine-specific demethylase 8 that has been identified as a potential target for the treatment of epilepsy.

The neurotransmitter systems involved in epilepsy have been extensively studied, and several mechanisms have been proposed to explain the pathological changes that occur in these systems. It is well established that epilepsy is associated with changes in the levels of key neurotransmitters, including GABA, which is a inhibitory neurotransmitter that plays a crucial role in the regulation of epileptic seizures. GABA levels are known to be decreased in individuals with epilepsy, and this decrease has been linked to the disrupted regulation of neuronal excitability and neurotransmission.

Several studies have also identified changes in the epigenetic landscape of epilepsy. Epigenetic changes, such as DNA methylation and histone modification, have been shown to play a crucial role in the regulation of gene expression and neurotransmission. Methylation of the GABA gene has been shown to reduce its levels, and this process is known to play a role in the pathogenesis of epilepsy. GABA is also known to be involved in the regulation of neuronal excitability and neurotransmission, and alterations in GABA levels have been implicated in the development of epileptic seizures.

KDM8, a lysine-specific demethylase 8, has been identified as a potential drug target and biomarker for epilepsy due to its role in the regulation of GABA levels and neurotransmission. KDM8 is a gene that has been shown to be expressed in the central nervous system and is involved in the demethylation of the GABA gene. The decreased expression of KDM8 has been observed in individuals with epilepsy, and this process is thought to contribute to the disrupted regulation of GABA levels and neurotransmission.

In addition to its role in GABA regulation, KDM8 has also been shown to play a role in the regulation of other neurotransmitters, including dopamine and glutamate. KDM8 has been shown to be involved in the metabolism of dopamine and glutamate, and alterations in these neurotransmitter levels have been implicated in the development of epileptic seizures. The dysregulation of neurotransmission has been a key feature of epilepsy, and the potential role of KDM8 in the regulation of these neurotransmitters makes it an attractive candidate for drug targeting and biomarker development in epilepsy.

In conclusion, KDM8 is a promising candidate for drug targeting and biomarker development in epilepsy due to its role in the regulation of GABA levels and neurotransmission. The decreased expression of KDM8 has been observed in individuals with epilepsy, and this process is thought to contribute to the disrupted regulation of GABA levels and neurotransmission. Further research is needed to fully understand the role of KDM8 in the pathogenesis of epilepsy and its potential as a drug target and biomarker.

Protein Name: Lysine Demethylase 8

Functions: Bifunctional enzyme that acts both as an endopeptidase and 2-oxoglutarate-dependent monooxygenase (PubMed:28847961, PubMed:29459673, PubMed:28982940, PubMed:29563586). Endopeptidase that cleaves histones N-terminal tails at the carboxyl side of methylated arginine or lysine residues, to generate 'tailless nucleosomes', which may trigger transcription elongation (PubMed:28847961, PubMed:29459673, PubMed:28982940). Preferentially recognizes and cleaves monomethylated and dimethylated arginine residues of histones H2, H3 and H4. After initial cleavage, continues to digest histones tails via its aminopeptidase activity (PubMed:28847961, PubMed:29459673). Upon DNA damage, cleaves the N-terminal tail of histone H3 at monomethylated lysine residues, preferably at monomethylated 'Lys-9' (H3K9me1). The histone variant H3F3A is the major target for cleavage (PubMed:28982940). Additionnally, acts as Fe(2+) and 2-oxoglutarate-dependent monooxygenase, catalyzing (R)-stereospecific hydroxylation at C-3 of 'Arg-137' of RPS6 and 'Arg-141' of RCCD1, but the biological significance of this activity remains to be established (PubMed:29563586). Regulates mitosis through different mechanisms: Plays a role in transcriptional repression of satellite repeats, possibly by regulating H3K36 methylation levels in centromeric regions together with RCCD1. Possibly together with RCCD1, is involved in proper mitotic spindle organization and chromosome segregation (PubMed:24981860). Negatively regulates cell cycle repressor CDKN1A/p21, which controls G1/S phase transition (PubMed:24740926). Required for G2/M phase cell cycle progression. Regulates expression of CCNA1/cyclin-A1, leading to cancer cell proliferation (PubMed:20457893). Also, plays a role in regulating alpha-tubulin acetylation and cytoskeletal microtubule stability involved in epithelial to mesenchymal transition (PubMed:28455245). Regulates the circadian gene expression in the liver (By similarity). Represses the transcriptional activator activity of the CLOCK-BMAL1 heterodimer in a catalytically-independent manner (PubMed:30500822). Negatively regulates the protein stability and function of CRY1; required for AMPK-FBXL3-induced CRY1 degradation (PubMed:30500822)

The "KDM8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KDM8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets